HIV Research and Treatment

This study demonstrates that non-antibody protein biologics can undergo affinity maturation in vivo, leading to improved binding affinity and neutralization potency against HIV-1.

This study shows that sequential immunization of macaques with engineered and native-like HIV-1 Env trimers elicits antibodies that neutralize by targeting non-closed Env conformations.

The paper identifies HIV-1 protein sequences in bacterial genomes, suggesting potential for false-positive HIV test results due to cross-reactivity with bacterial proteins.

The paper develops a multiplexed digital PCR assay to quantify total and intact HIV-1 reservoirs, showing it is more specific than existing methods and enables high-throughput analysis.

The paper constructs and characterizes a subtype C HIV-1 reporter virus, HIV-1IndieC1-mGL, showing it retains parental characteristics and is responsive to methamphetamine.

The paper shows that cognate antigen engagement in CD4+ T cells on long-term ART increases HIV-1 transcription through T cell activation, suggesting a role in viral rebound.

This study compares immune profiles of children living with HIV who started antiretroviral treatment at different times and durations, finding distinct immune differences between early and delayed treatment groups.

This paper develops a multi-task learning model to predict HIV-1 resistance to multiple broadly neutralizing antibodies, showing it reduces subtype bias and identifies co-resistance patterns.

This study shows that HIV-1 budding requires MICAL1-mediated actin disassembly at the plasma membrane, with Rab35 also playing a role in this process.

This study compares vaccine-elicited and naturally elicited antibodies' recognition of HIV-1 fusion peptide sequences, finding that naturally elicited antibodies show greater tolerance to sequence variation.

This study identifies an occluded-intermediate state in the HIV-1 Env trimer transition pathway using molecular dynamics and smFRET, revealing new structural features and antibody recognition.

This study shows Enoxacin reduces HIV-1 replication by downregulating hsa-miR-132-3p in T-cells, suggesting potential for antiviral therapy through miRNA modulation.

This study uses single-cell RNA and ATAC sequencing to identify KLF2 as a key regulator of HIV-1 persistence and Th17 cell dysfunction in early infection.

This study shows that Cyclophilin A promotes HIV-1 integration by enhancing preintegration complex activity, revealing a new role for CypA in the viral life cycle.

The paper shows that CBP/p300 inhibitors reverse HIV-1 latency in T-cells by altering acetylation at the HIV-1 LTR, and that this effect is distinct from HDACi mechanisms.

The paper uses electron tomography to visualize HIV-1 virions trapped by fusion inhibitors in infected tissues, revealing pre-hairpin intermediates linked to host cells.

The paper examines how HIV exposure in infants affects maternal microchimeric T cells, finding reduced levels in CD8+ T cells among HIV-exposed uninfected infants.

This paper demonstrates that PZ703b, a dual Bcl-2/Bcl-xL degrader, reverses HIV latency and reduces the replication-competent reservoir in ex vivo CD4+ T cells from ART-suppressed patients.

The paper shows CD4 downregulation precedes Env expression in HIV-1-infected cells, making them resistant to non-neutralizing antibody-mediated ADCC.

The paper identifies a gut microbial signature predictive of RhCMV/SIV vaccine efficacy in rhesus macaques using 16S rRNA analysis and compositional data techniques.

This study examines metabolic reprogramming in immune cells during HIV infection and after antiretroviral therapy using single-cell RNA sequencing and pathway analysis.

The paper measures CSF proteins in HIV-1 infected and uninfected individuals, identifying patterns of protein changes associated with CNS injury and treatment effects.

The paper introduces the XbnAb cohort, a large cohort of 305 people with HIV-1 broadly neutralizing antibody activity, to support HIV vaccine research.

This paper shows that inhibiting the Super Elongation Complex (SEC) with KL-2 increases HIV-1 transcription and reactivates latent virus, especially when combined with other latency reversing agents.

This study immunized cows with HIV Env trimers to generate broadly neutralizing antibodies targeting the V2-apex, revealing ultralong CDRH3 antibodies outcompete shorter ones in the response.

This paper combines three CD4-induced antibodies with a CD4-mimetic to achieve potent ADCC activity against HIV-1-infected cells.

The paper compares two approaches for predicting HIV-1 neutralization by combination antibody regimens, finding the combine-then-predict approach superior for binary outcomes and at least as good for continuous outcomes.

The paper compares the fraction and total number of HIV-infected cells with unspliced RNA in controllers and non-controllers, finding that viremic control is linked to fewer infected cells, not a lower fraction of infected cells with HIV usRNA.

This paper identifies a heterocyclic compound, HT-7, that inhibits HIV-1 release by increasing cell surface BST2 expression with minimal cellular toxicity.